DeepMed Research

Ciclesonide

Generic Name: Ciclesonide

Brand Names: Alvesco, Omnaris, Zetonna

Drug Type: Small Molecule

Chemical Formula: C_₃₂H_₄₄O_₇

CAS Number: 126544-47-6

Unique Ingredient Identifier: S59502J185

Background: Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco.

Indication: For the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older.

Associated Conditions: Asthma, Bronchoconstriction, Chronic Obstructive Pulmonary Disease (COPD), Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis

Clinical Trials

Inhaled Ciclesonide Study in Preterm Infants

Phase 1

Recruiting

Conditions: Bronchopulmonary Dysplasia

Interventions: Drug: Alvesco Inhalant Product

First Posted Date: 2024-09-19

Last Posted Date: 2025-05-21

Lead Sponsor: Children's Mercy Hospital Kansas City

Target Recruit Count: 30

Registration Number: NCT06589245

Locations: 🇺🇸
Children's Mercy Kansas City, Kansas City, Missouri, United States

PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V

Phase 2

Recruiting

Conditions: Covid19

Interventions: Drug: Placebo
Drug: Niclosamide
Drug: Ciclesonide
Drug: Sotrovimab

First Posted Date: 2021-05-03

Last Posted Date: 2024-03-22

Lead Sponsor: Cambridge University Hospitals NHS Foundation Trust

Target Recruit Count: 5000

Registration Number: NCT04870333

Locations: 🇬🇧
Queen Elizabeth Hospital, King's Lynn, NHS Foundation Trust, King's Lynn, United Kingdom
🇬🇧
University Hospitals of Leicester NHS Trust, Leicester, United Kingdom
🇬🇧
Imperial College Healthcare NHS Trust, London, United Kingdom

and more 42 locations

Inhaled Ciclesonide for Outpatients With COVID19

Phase 2

Terminated

Conditions: COVID 19

Interventions: Drug: Normal Saline intranasal and placebo inhaler
Drug: Ciclesonide
Drug: Ciclesonide nasal

First Posted Date: 2020-06-17

Last Posted Date: 2022-06-10

Lead Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre

Target Recruit Count: 215

Registration Number: NCT04435795

Locations: 🇨🇦
University of British Columbia, Vancouver, British Columbia, Canada
🇨🇦
McGill University Health Center, Montreal, Quebec, Canada
🇨🇦
Sunnybrook Hospital, Toronto, Ontario, Canada

Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19)

Phase 2

Conditions: Sars-CoV2
Covid-19
Pneumonia, Viral

Interventions: Drug: Ciclesonide Inhalation Aerosol

First Posted Date: 2020-05-08

Last Posted Date: 2022-02-02

Lead Sponsor: Ola Blennow, MD, PhD

Target Recruit Count: 98

Registration Number: NCT04381364

Locations: 🇸🇪
Södra Älvsborg hospital, Borås, Sweden
🇸🇪
Danderyd Hospital, Danderyd, Sweden
🇸🇪
Halmstad hospital, Halmstad, Sweden

and more 8 locations

A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients

Phase 3

Completed

Conditions: COVID-19

Interventions: Drug: Placebo
Drug: Ciclesonide

First Posted Date: 2020-05-06

Last Posted Date: 2023-02-09

Lead Sponsor: Covis Pharma S.à.r.l.

Target Recruit Count: 400

Registration Number: NCT04377711

Locations: 🇺🇸
University of Buffalo, Buffalo, New York, United States

Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation

Phase 2

Completed

Conditions: Corona Virus Infection
Sars-CoV2

Interventions: Drug: interferon β-1b
Dietary Supplement: Vitamins
Drug: Ciclesonide
Drug: Telmisartan

First Posted Date: 2020-04-22

Last Posted Date: 2022-02-04

Lead Sponsor: University Hospital, Bordeaux

Target Recruit Count: 412

Registration Number: NCT04356495

Locations: 🇫🇷
Bordeaux university Hospital, Bordeaux, France
🇫🇷
CNGE, Paris, France
🇫🇷
CHU de Montpellier, Montpellier, France

and more 4 locations

A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19

Phase 2

Completed

Conditions: COVID-19

Interventions: Drug: Ciclesonide Metered Dose Inhaler [Alvesco]

First Posted Date: 2020-04-01

Last Posted Date: 2021-06-24

Lead Sponsor: Korea University Guro Hospital

Target Recruit Count: 68

Registration Number: NCT04330586

Locations: 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of

The Mannitol-Asthma-Ciclesonide-Study

Phase 4

Completed

Conditions: Asthma, Bronchial

Interventions: Drug: Ciclesonide

First Posted Date: 2019-02-15

Last Posted Date: 2019-07-25

Lead Sponsor: Cantonal Hosptal, Baselland

Target Recruit Count: 72

Registration Number: NCT03839433

Ciclesonide vs Fluticasone Nasal Sprays in Nasal Poplyposis

Phase 3

Conditions: Chronic Rhinosinustis With Polyps

Interventions: Drug: Ciclesonide
Drug: Fluticasone

First Posted Date: 2016-01-28

Last Posted Date: 2016-01-28

Lead Sponsor: Tehran University of Medical Sciences

Target Recruit Count: 32

Registration Number: NCT02665806

A Study Comparing The Bioequivalence Of Ciclesonide Nasal Spray (Apotex, Inc.) To That Of Omnaris™ Nasal Spray (Sepracor, Inc.) In The Treatment Of Seasonal Allergic Rhinitis

Phase 3

Completed

Conditions: Seasonal Allergic Rhinitis

Interventions: Drug: Ciclesonide nasal spray, 50 μg per actuation.

First Posted Date: 2014-10-24

Last Posted Date: 2014-10-24

Lead Sponsor: Apotex Inc.

Target Recruit Count: 580

Registration Number: NCT02273817

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy